Clinical trials: Carcinoma of Prostate (Disorder)
Localized Prostate Cancer, Active Surveillance for Prostate Cancer
Active Surveillance Exercise Clinical Trial
This phase 2, open-label, dual-center, two-arm randomized controlled trial (RCT) investigates the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance).
- Trial name
- ASX (NCT02435472)
- Testing
- Exercise, Cardiopulmonary Exercise Test (CPET)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of California, San Francisco
Prostate Neoplasm
Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI
This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
- Trial name
- NCT06315595
- Testing
- Non-Interventional Study
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostate Cancer
Sarcopenia in Older Patient With Prostate Cancer, Prevalence and Incidence After Androgen Deprivation Therapy
Prostate cancer is the most common cancer among men 50 years and older and mainly affets patients 75 years old. Androgen deprivation therapy is indicatated in intermediates and high risks form of prostate cancer, in association…
- Trial name
- HoSAGE (NCT04484246)
- Testing
- Prevalence of sarcopenia in older patient with prostate cancer
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Prostate Cancer
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Prostate cancer patients diagnosed with a biochemical recurrence and limited metastases are conventionally treated with androgen deprivation therapy.
- Trial name
- NCT01558427
- Testing
- Surveillance, Salvage treatment
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- University Hospital, Ghent
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Prostate Cancer
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in…
- Trial name
- NCT00667888
- Testing
- Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Urinary Bladder Neoplasms, Prostatic Neoplasms
Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™
The purpose of the present study is to compare the effect of PEEP on arterial oxygen partial pressure in elderly patients undergoing urologic surgery using LMA supreme™ in a lithotomy position.
- Trial name
- NCT03390127
- Testing
- PEEP
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Asan Medical Center
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA)…
- Trial name
- CATCH-177 (NCT06738303)
- Testing
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
The combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. The purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will…
- Trial name
- KHAD (NCT00673127)
- Testing
- Ketoconazole, Hydrocortisone and Dutasteride
- Where
- 7 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Beth Israel Deaconess Medical Center
Prostatic Neoplasms
Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
The purpose of the study is to evaluate the usefulness of 3-T magnetic resonance imaging (MRI) in the evaluation of suspected prostate cancer.
- Trial name
- NCT01357512
- Testing
- magnetic resonance imaging, Siemens
- Where
- Finland
- Volunteers
- 130 people
- Sponsor
- University of Oulu
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to treatment with hormones, has come back, or has…
- Conditions
- Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02935205
- Testing
- Enzalutamide, Indomethacin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mamta Parikh
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Trial name
- NCT01251861
- Testing
- Akt Inhibitor MK2206, Bicalutamide, Clinical Observation
- Where
- 198 sites in United States, Ireland
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Precancerous/Nonmalignant Condition, Prostate Cancer
Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Vitamin E, selenium, and soy protein may be effective in preventing the development of prostate…
- Trial name
- NCT00064194
- Testing
- selenium, soy protein isolate, vitamin E
- Where
- 3 sites in Canada
- Volunteers
- 310 people
- Sponsor
- NCIC Clinical Trials Group
Prostatic Neoplasms
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks)…
- Trial name
- NCT00235794
- Testing
- temsirolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Prostate Cancer
Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical
Does nutraceutical N-111 lower the number of side effects occurring during ADT + External Beam Radiation (EBR) prostate cancer treatment?
- Trial name
- NCT06643494
- Testing
- N-111
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Optimal Health Research
Circulating Tumor Cell, Metastatic Prostate Cancer
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
After failure on docetaxel, which has been the standard first line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), several treatment options are currently available.
- Trial name
- CABA-V7 (NCT03050866)
- Testing
- Cabazitaxel, Antihistamine, Corticosteroid
- Where
- 9 sites in Netherlands
- Volunteers
- 140 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer
Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Luteinizing hormone-releasing hormone agonists may lessen the amount of androgens made by the body.
- Trial name
- SHIP0804 (NCT00664456)
- Testing
- Adjuvant therapy, Neoadjuvant therapy, Brachytherapy（iodine I 125）
- Where
- Japan
- Volunteers
- 421 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.